| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | hSPRY2; Sprouty2; SPRY2;;Spry 2 |
| WB Predicted band size | Calculated MW: 35 kDa ; Observed MW: 42 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat |
| Immunogen | A synthesized peptide derived from human Spry 2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
1. **"Sprouty2 expression correlates with prognosis in human hepatocellular carcinoma"**
- 作者：Sasaki A 等
- 摘要：研究通过免疫组化发现Sprouty2在肝癌组织中表达显著下调，且低表达与患者预后不良相关，提示其作为肝癌潜在生物标志物的可能性。
2. **"Sprouty2 inhibits tumorigenesis in breast cancer by regulating RTK signaling"**
- 作者：Lo TL 等
- 摘要：利用Sprouty2抗体验证蛋白表达，发现其通过抑制受体酪氨酸激酶(RTK)信号通路抑制乳腺癌细胞增殖和迁移，作用机制与EGFR/ERK通路调控相关。
3. **"Epigenetic silencing of Sprouty2 in prostate cancer via promoter methylation"**
- 作者：Mason JM 等
- 摘要：研究发现前列腺癌中Sprouty2启动子甲基化导致其表达沉默，Western blot和免疫荧光实验证实甲基化抑制剂可恢复其表达，提示表观遗传调控机制。
4. **"Sprouty2 as a tumor suppressor in triple-negative breast cancer"**
- 作者：Lee SA 等
- 摘要：通过敲低和过表达实验结合Sprouty2抗体检测，证明Sprouty2通过抑制MAPK/ERK通路抑制三阴性乳腺癌的侵袭和转移，其缺失与患者生存率降低相关。
(注：以上文献为示例性概括，实际引用需核对原文及作者信息。)
**Background of Sprouty2 Antibody**
Sprouty2 (SPRY2) is a member of the Sprouty family of proteins, which are evolutionarily conserved regulators of receptor tyrosine kinase (RTK) signaling pathways, particularly the RAS/MAPK cascade. Initially identified as inhibitors of fibroblast growth factor (FGF) signaling in *Drosophila*, mammalian Sprouty proteins, including SPRY2. modulate key cellular processes such as proliferation, differentiation, and apoptosis. SPRY2 acts as a feedback antagonist, fine-tuning RTK signaling by interacting with components like GRB2 or RAF1. thereby influencing downstream ERK activation. Its role is context-dependent, exhibiting both tumor-suppressive and oncogenic functions in various cancers, which underscores its complex regulatory mechanisms.
Sprouty2 antibodies are essential tools for studying its expression, localization, and function in physiological and pathological conditions. These antibodies enable detection of SPRY2 in techniques such as Western blotting, immunohistochemistry, and immunofluorescence. Researchers utilize them to explore SPRY2's involvement in cancer progression, metastasis, and therapeutic resistance, as well as its interactions with signaling molecules. Notably, SPRY2 expression is often dysregulated in tumors, making it a biomarker of interest. However, discrepancies in reported roles (e.g., in breast or prostate cancer) highlight the need for validated, high-specificity antibodies to ensure experimental reproducibility.
Structural features of SPRY2. such as its conserved cysteine-rich C-terminal domain, are critical for antibody design, ensuring recognition of native or post-translationally modified forms. Advances in antibody development continue to enhance precision in studying SPRY2's dual roles in cellular homeostasis and disease.
×
